PABLO MÍNGUEZ GABIÑA-rekin lankidetzan egindako argitalpenak (9)
2021
-
A retrospective study on the potential of 99mTc-HDP imaging before therapy for individualizing treatments with 223Ra-Cl2 for metastatic castration resistant prostate cancer
Medical Physics, Vol. 48, Núm. 3, pp. 1395-1403
-
Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: Toxicity, prostatespecific antigen kinetics, and cancer control
Journal of Contemporary Brachytherapy, Vol. 13, Núm. 1, pp. 12-17
2020
-
MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
Clinical and Translational Radiation Oncology, Vol. 24, pp. 135-139
-
Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial
Radiotherapy and Oncology, Vol. 146, pp. 16-20
2019
-
Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study
Radiotherapy and Oncology, Vol. 135, pp. 13-18
2018
-
Detection and quantification of 223Ra uptake in bone metastases of patients with castration resistant prostate carcinoma, with the aim of determining the absorbed dose in the metastases
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 37, Núm. 1, pp. 20-27
-
Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial
Radiotherapy and Oncology, Vol. 126, Núm. 2, pp. 278-282
2016
-
Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial
Radiotherapy and Oncology, Vol. 119, Núm. 1, pp. 91-96
2014
-
Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy
Journal of Contemporary Brachytherapy, Vol. 6, Núm. 2, pp. 154-160